Non-small cell lung cancer+1
RecruitingLong-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications
Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications
- Disease:Non-small cell lung cancerMetastatic malignant melanoma
- Substances:Dabrafenib MesylateTrametinib
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Dabrafenib Mesylate
- Sponsor:Novartis Pharma AG












